VPC
FATE icon

Vestal Point Capital’s Fate Therapeutics FATE Stock Holding History

Vestal Point Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,725,000
Closed -$1.69M – 99
2025
Q4 		$1.69M Sell
1,725,000
-790,000
-31% -$949K 0.06% 72
2025
Q3 		$3.17M Hold
2,515,000
– – 0.14% 72
2025
Q2 		$2.82M Sell
2,515,000
-850
-0% -$988 0.15% 60
2025
Q1 		$1.99M Buy
2,515,850
+50,850
+2% +$62.3K 0.14% 54
2024
Q4 		$4.07M Buy
2,465,000
+780,000
+46% +$1.97M 0.24% 57
2024
Q3 		$5.9M Sell
1,685,000
-315,000
-16% -$1.23M 0.45% 46
2024
Q2 		$6.56M Buy
2,000,000
+1,200,000
+150% +$5.25M 0.49% 42
2024
Q1 		$5.87M Sell
800,000
-490,000
-38% -$3.03M 0.49% 41
2023
Q4 		$4.82M Buy
+1,290,000
New +$3.05M 0.51% 33

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vestal Point Capital's FATE Position: Q1 2026 in Review

Vestal Point Capital sold out of Fate Therapeutics (FATE) in Q1 2026, closing a stake of 1,725,000 shares — an estimated $1.69M sold.

Vestal Point Capital first reported a position in FATE in Q4 2023 and held it in 9 quarters. The position peaked at $6.56M in Q2 2024. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Vestal Point Capital reported no remaining Fate Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Vestal Point Capital sold 1,725,000 Fate Therapeutics shares in Q1 2026, an estimated $1.69M.
  • Vestal Point Capital first reported a position in Fate Therapeutics in Q4 2023 and held it in 9 quarters.
  • Vestal Point Capital's Fate Therapeutics position peaked at $6.56M in Q2 2024.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.